BostonGene vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
BostonGene is an AI-powered precision oncology company using multiomics and tumor microenvironment analysis to guide cancer treatment; won Frost & Sullivan's 2025 Global Tech Innovation Award and partnered with Johnson & Johnson.
About
BostonGene is a biomedical company founded in 2015 that applies artificial intelligence and next-generation sequencing to decode cancer patients' molecular profiles, enabling oncologists and biopharma researchers to make more precise treatment decisions. Its AI-powered multiomics platform analyzes tumor microenvironments, genomic drivers, and immune system interactions to identify the most effective therapy for each patient, reducing trial-and-error in cancer treatment selection.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.